Reading the Tape: Visa, Broadcom, and UnitedHealth in August 2026

One of the most practical skills a retail trader can develop is the ability to read a chart without immediately reaching for a conclusion. Price data tells a story, but that story is best understood in layers: where is the instrument relative to its recent range? What does short- and medium-term momentum look like? Where would a disciplined trader place a logical reference point for invalidation? This article walks through exactly that process for three widely followed names — Visa (V), Broadcom (AVGO), and UnitedHealth Group (UNH) — using current August 2026 data available on Montbon Analytics.

The Framework: Four Lenses Before Any Decision

Before diving into individual instruments, it helps to establish a repeatable reading framework. Technical analysts typically examine four dimensions in sequence:

• Trend direction: Is price making higher highs and higher lows, lower highs and lower lows, or moving sideways?
• Position within recent range: Where does the current price sit relative to the highest and lowest points of the past three months? A reading near 100% means price is at the top of its range; near 0% means it is at the bottom.
• Short- vs. medium-term momentum: Comparing the five-day change to the twenty-one-day change reveals whether a move is accelerating, decelerating, or diverging across timeframes.
• Invalidation levels: Every technical thesis has a price level at which it stops making sense. Identifying that level before entering any position is a core discipline.

With that framework in place, let us apply it to each instrument in turn.

Visa (V): At the Top of Its Range — What That Means Structurally

Readers who follow Visa's live technical analysis on Montbon will recognise the picture immediately: at $370.47, V is sitting precisely at the top of its three-month range. The range low over that period is $312.40, giving a spread of roughly $58. A position-in-range reading of 100.0% means the current price equals the three-month high — there is no overhead range to compare against, because the instrument has just set a new local peak.

From a trend-reading perspective, this is unambiguously constructive short-term price behaviour. The five-day change of +1.1% and the twenty-one-day change of +6.6% are both positive, and the twenty-one-day figure is notably larger than the five-day one. This pattern — where the medium-term return exceeds the short-term return — is consistent with a steady, broad advance rather than a sharp spike. It suggests the move has been building over several weeks rather than arriving in one volatile session.

What should a technically oriented reader watch for at this juncture? When price reaches a multi-month high, one of two things structurally can happen: consolidation near the highs, or a continuation that creates new range structure above. Neither is predictable in advance. What is measurable is the distance to the prior range low. A trader framing a hypothetical scenario would note that $312.40 represents the boundary where the three-month uptrend would be fully retraced — a level that acts as a natural structural reference for invalidation of the bullish trend reading.

Recent headlines reference consumer confidence data alongside Visa earnings, which provides context for why the stock has attracted attention, though a purely technical reader focuses on what price itself is doing rather than the narrative.

Broadcom (AVGO): Mid-Range Positioning After a Strong Short-Term Push

Broadcom presents a meaningfully different picture. The Broadcom technical chart on Montbon shows a stock currently trading at $420.57, sitting at approximately the midpoint of its three-month range — 50.0% between the $360.45 low and the $480.81 high. That positioning is significant because it means AVGO has overhead range to contend with: roughly $60 of prior price activity sits between the current level and the three-month high.

The momentum picture here is the most notable aspect of the data. AVGO's five-day change is +8.4%, compared to a twenty-one-day change of +8.2%. These two figures being nearly identical tells a specific story: almost the entire medium-term gain has been compressed into the most recent week. That kind of momentum surge can reflect a catalyst-driven repricing event — in Broadcom's case, headlines around AI chip developments and acquisition activity in the semiconductor space are consistent with such a dynamic.

A technically disciplined reader would approach this situation carefully. Sharp short-term moves that arrive at the midpoint of a prior range often face natural friction: traders who bought near the three-month high of $480.81 and are sitting on losses may look to reduce exposure as price recovers toward their entry level. This phenomenon — sometimes called overhead supply — is not a prediction; it is simply a structural observation about where prior transactions occurred.

For reference framing, the three-month low at $360.45 represents the boundary of the current range structure, while $480.81 marks the level that would need to be exceeded to establish a new multi-month high. Both are useful reference points regardless of directional bias.

UnitedHealth Group (UNH): Reading a Pullback Within an Established Range

UnitedHealth Group offers the most contrasting setup of the three. UNH's technical overview on Montbon shows a stock at $403.97, down 4.2% over five days and down 5.1% over twenty-one days. Unlike Visa and Broadcom, where both timeframes are positive, UNH is in a short-to-medium-term downswing — and the twenty-one-day decline is slightly larger than the five-day decline, suggesting the weakness has been spread across several weeks rather than concentrated in a single session.

The range context is important here. UNH's three-month high is $436.35 and the low is $367.64, giving a range of roughly $69. At $403.97, the stock sits at approximately 53% of that range — near the midpoint, having pulled back from higher levels. This means UNH is neither at an obvious support floor nor pressing against overhead resistance; it occupies the middle ground, where the path of least resistance is least clear.

A structured trader reading this situation would note several reference points. The $436.35 high marks the level that would need to be reclaimed for the medium-term trend to reassert itself. The $367.64 low represents the boundary where range support would be tested. The current price at roughly $404 sits between these poles with no definitive structural lean in either direction based purely on position-in-range.

The momentum divergence — losses on both five-day and twenty-one-day timeframes — is the element that most clearly distinguishes UNH from the other two instruments in this review. Whether that divergence reflects a temporary retracement or the beginning of something more persistent is precisely what technical analysts monitor through developing price action, not what they project in advance.

Synthesising the Three Setups: A Reading, Not a Recommendation

Putting these three instruments side by side illustrates how different structural contexts can coexist in the same market at the same time. Visa is at a range extreme with sustained momentum. Broadcom is mid-range with compressed short-term momentum following a sharp move. UnitedHealth is mid-range with negative momentum on both measured timeframes. Each setup calls for a different type of analytical attention:

• Range extremes (like V at 100%) prompt questions about continuation versus consolidation.
• Mid-range positioning after a catalyst spike (like AVGO) prompts questions about overhead supply and whether the move has sufficient follow-through.
• Mid-range positioning with negative momentum (like UNH) prompts questions about whether a support level will be tested and where the structural floor lies.

None of these framings tells a trader what to do. They tell a trader what to watch — and that distinction is at the heart of disciplined technical reading.

Disclaimer: This article is produced by Montbon Analytics for educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any financial instrument. All data referenced reflects publicly available market information as of August 2026. Trading financial instruments involves significant risk of loss and may not be suitable for all investors. Past price behaviour does not guarantee future results. Always conduct your own research and, where appropriate, consult a qualified financial adviser before making any investment decision.